Updates are available Correction dated 2023-10-23
Click to view Correction: https://doi.org/10.1038/s41467-023-42562-2
-
Authors
Al-Sawaf, Othman http://orcid.org/0000-0001-9895-0570
Zhang, Can
Jin, Hyun Yong
Robrecht, Sandra
Choi, Yoonha
Balasubramanian, Sandhya
Kotak, Alex
Chang, Yi Meng
Fink, Anna Maria
Tausch, Eugen
Schneider, Christof
Ritgen, Matthias
Kreuzer, Karl-Anton
Chyla, Brenda
Paulson, Joseph N.
Pallasch, Christian P. http://orcid.org/0000-0001-5675-6905
Frenzel, Lukas P.
Peifer, Martin http://orcid.org/0000-0002-5243-5503
Eichhorst, Barbara
Stilgenbauer, Stephan http://orcid.org/0000-0002-6830-9296
Jiang, Yanwen
Hallek, Michael http://orcid.org/0000-0002-7425-4455
Fischer, Kirsten http://orcid.org/0009-0006-6169-9152
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (467697427, SFB 1530 Z01/B01, SFB 1530 project C04)
- License Information
-
More Information
Article History
Received: 24 August 2022
Accepted: 24 March 2023
First Online: 18 April 2023
Change Date: 23 October 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-42562-2
Competing interests
: O.A.S.: Advisory Board (Ascentage, AstraZeneca, AbbVie, BeiGene, Eli Lilly, Gilead, Janssen, Roche), speaker honoraria (Adaptive, AstraZeneca, AbbVie, BeiGene, Eli Lilly, Gilead, Janssen, Roche), research funding (BeiGene, AbbVie, Janssen, Roche). H.Y.J.: Employment with Genentech/Hoffmann-la Roche. S.B.: Employment with Genentech/Hoffmann-la Roche. A.K.: Employment with Hoffmann-la Roche. Y.C.: Employment with Genentech/Hoffmann-la Roche. A.M.F.: reports personal fees from Celgene, Janssen, Hoffmann-La Roche. E.T.: Advisory Board (Abbvie, Janssen-Cilag, BeiGene), speaker honoraria (AstraZeneca, Abbvie, BeiGene, Gilead, Janssen, Roche), research funding (Roche, Abbvie, Gilead). C.S.: Speaker honoraria (AstraZeneca, AbbVie). M.R.: reports grants from F.Hoffman-La Roche Ltd; personal fees from F. Hoffmann-La Roche Ltd, AbbVie. K.A.K.: reports grants from F. Hoffmann-La Roche Ltd, Abbvie, during the conduct of the study; personal fees from F. Hoffmann-La Roche Ltd, AbbVie. B.C.: Employment with AbbVie. C.P.P.: Speaker honoraria (AstraZeneca, Pfizer) Research Funding (Gilead Sciences) Advisory Board (Abbvie) J.P.: Employment with Genentech/Hoffmann-la Roche. B.E.: Grants and personal fees from F. Hoffmann-La Roche Ltd, AbbVie, AstraZeneca, BeiGene, and Janssen, personal fees from Celgene, Novartis, ArQule, Gilead, Oxford Biomedica (UK), Adaptive Biotechnologies, Hexal. S.S.: Grants, personal fees and non-financial support from AbbVie, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche Ltd, Janssen, Novartis, Pharmacyclics, Sunesis, Verastem. Y.J.: Employment with Genentech/Hoffmann-la Roche, stock (Genentech). MH: Honoraria (Roche, Janssen, AbbVie, Gilead Sciences, AstraZeneca), Consulting or Advisory Role (Janssen, AbbVie, Gilead Sciences, Genentech/Roche, AstraZeneca), Speakers’ Bureau: Janssen, AbbVie, Gilead Sciences, Roche/Genentech, AstraZeneca), Research Funding (Roche, AbbVie, Janssen, Gilead Sciences, AstraZeneca), Travel, Accommodations, Expenses (Roche, Janssen). K.F.: Advisory Board (AstraZeneca, AbbVie), speaker honoraria (AbbVie, Roche), research funding (AbbVie, Roche). The remaining authors declare no other competing interests.
